CN1336383A - Giant web bombinin and its prepn. and pharmaceutical application - Google Patents
Giant web bombinin and its prepn. and pharmaceutical application Download PDFInfo
- Publication number
- CN1336383A CN1336383A CN 00122414 CN00122414A CN1336383A CN 1336383 A CN1336383 A CN 1336383A CN 00122414 CN00122414 CN 00122414 CN 00122414 A CN00122414 A CN 00122414A CN 1336383 A CN1336383 A CN 1336383A
- Authority
- CN
- China
- Prior art keywords
- bombina
- grandis
- alanine
- leucine
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710114744 Bombinin Proteins 0.000 title description 2
- 102000013585 Bombesin Human genes 0.000 claims abstract description 29
- 108010051479 Bombesin Proteins 0.000 claims abstract description 29
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims abstract description 29
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 22
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims abstract description 18
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims abstract description 18
- 241000269348 Bombina Species 0.000 claims abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 16
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 11
- 229920001184 polypeptide Polymers 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000005342 ion exchange Methods 0.000 claims abstract description 10
- 230000028327 secretion Effects 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims abstract description 8
- 238000002523 gelfiltration Methods 0.000 claims abstract description 7
- 230000000813 microbial effect Effects 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 238000004440 column chromatography Methods 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000011521 glass Substances 0.000 claims abstract description 4
- 239000007791 liquid phase Substances 0.000 claims abstract 2
- 239000012071 phase Substances 0.000 claims abstract 2
- 239000002244 precipitate Substances 0.000 claims abstract 2
- 241000340668 Bombina maxima Species 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 12
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 230000002538 fungal effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 description 15
- 229920005654 Sephadex Polymers 0.000 description 13
- 239000012507 Sephadex™ Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 241000233866 Fungi Species 0.000 description 6
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229910000831 Steel Inorganic materials 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060003100 Magainin Proteins 0.000 description 3
- 241000228143 Penicillium Species 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000228197 Aspergillus flavus Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000565648 Campanula medium Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 2
- 241000162069 Fejervarya cancrivora Species 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 241000270959 Pelophylax nigromaculatus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 108010062940 pexiganan Proteins 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241000269340 Bombina orientalis Species 0.000 description 1
- 241000269338 Bombina variegata Species 0.000 description 1
- 241001415440 Bufo gargarizans Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000149140 Fejervarya limnocharis Species 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000235525 Rhizomucor pusillus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000149142 Sylvirana guentheri Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于生物医学领域。大蹼铃蟾抗菌肽,为从中国两栖类动物大蹼铃蟾皮肤分泌物中分离得到的一种单链多肽,分子量2697.6,等电点10.2,多肽一级全序列结构为:NH2—GIGGVLLSAGKAALKGLAKVLAAKYANN-NH2。制备方法是将活体大蹼铃蟾用水清洗干净,置于带盖的玻璃容器中,滴加无水乙醚,密闭容器3—5分钟,可见大量的泡沫状物质从大蹼铃蟾皮肤分泌出来,收集分泌物,离心去除沉淀、冷冻干燥后,经离子交换、凝胶过滤、高压液相反相柱层析分离纯化后即得到。大蹼铃蟾抗菌肽具有广谱和显著的抑制细菌和真菌生长作用,作为广谱抗微生物物质在制备治微生物感染疾病药物的应用。The invention belongs to the field of biomedicine. Bombina grandis antimicrobial peptide is a single-chain polypeptide isolated from the skin secretion of Bombina grandis, a Chinese amphibian, with a molecular weight of 2697.6 and an isoelectric point of 10.2 . -NH 2 . The preparation method is to clean the living Bombina grandis with water, put it in a glass container with a cover, add anhydrous ether dropwise, and seal the container for 3-5 minutes. A large amount of foamy substances can be seen secreted from the skin of the Bombina grandis. The secretion is collected, centrifuged to remove the precipitate, freeze-dried, separated and purified by ion exchange, gel filtration, and high-pressure liquid phase phase column chromatography. The bombesin antibacterial peptide has broad-spectrum and significant antibacterial and fungal growth effects, and is used as a broad-spectrum antimicrobial substance in the preparation of drugs for treating microbial infection diseases.
Description
本发明提供一种大蹼铃蟾抗菌肽及其制备方法和在制药中的应用,属生物医学领域。The invention provides a bombesin antimicrobial peptide and its preparation method and application in pharmacy, belonging to the field of biomedicine.
自从抗生素发明以来,人类在控制和治疗微生物感染疾病中取得了较大的成就,但随着药物的持续使用,目前微生物抗药性已成为临床微生物感染疾病治疗的重大问题,以至于某些病原细菌已没有临床治疗的一线药物。万古霉素抗性的葡萄球菌、肠球菌以及其他革兰氏阴性感染疾病目前均是世界范围内的临床难题。三类主要引起脑膜炎的细菌在临床上也出现了强的抗药性,抗青霉素、氯霉素脑膜炎双球菌,肺炎球菌,对抗新头孢菌素抗生素的肺炎球菌也广泛出现。因此新一类抗生素的研制已成为当务之急和国际上的热点。与目前广泛使用的抗生素相比,多肽抗生素具有很多优点:如在最小作用浓度时,快速而广谱的杀灭微生物(包括目前临床抗药菌),对真菌也有抑制作用,抗性菌株生成性小,对局部感染和全身感染都有效,正成为新一类抗生素,其研制目前受到广泛重视。Since the invention of antibiotics, humans have made great achievements in the control and treatment of microbial infection diseases, but with the continuous use of drugs, microbial resistance has become a major problem in the treatment of clinical microbial infection diseases, so that some pathogenic bacteria There is no first-line drug for clinical treatment. Vancomycin-resistant staphylococci, enterococci, and other Gram-negative infections are currently a worldwide clinical problem. The three types of bacteria that mainly cause meningitis also have strong drug resistance clinically. Penicillin-resistant, chloramphenicol-resistant meningococcus, pneumococcus, and pneumococcus resistant to new cephalosporin antibiotics also widely appear. Therefore, the development of a new class of antibiotics has become a top priority and an international hotspot. Compared with the widely used antibiotics at present, polypeptide antibiotics have many advantages: such as rapid and broad-spectrum killing of microorganisms (including current clinical drug-resistant bacteria) at the minimum effective concentration, and inhibitory effect on fungi, and the ability to generate resistant strains Small, effective for both local infection and systemic infection, it is becoming a new class of antibiotics, and its development is currently receiving extensive attention.
很多两栖类动物在中国属于传统中药和民族药物而广泛应用,如中华蟾蜍(Bufo gargarizans),大蹼铃蟾(Bombina maxima),黑斑蛙(pelophylaxnigromaculata),沼蛙(Hylarana guentheri)和泽蛙(Euphlyctis limnocharis)等。这些两栖类动物的皮肤和内脏具有广泛的药理活性和临床疗效,已报道药理活性有广谱抗微生物作用、抗肿瘤、局部麻醉、镇痛、免疫调节、心血管系统作用等。在国外,两栖类皮肤特定药理活性单体化合物的寻找已是新药发明的热点,据国外文献报道,从爪蟾(Xenopus laevis)皮肤分泌液获得的抗菌肽Magainin具广谱抗微生物作用,同时具有抗肿瘤活性,在美国已获准作为广谱抗菌药物,其基因工程产品已进入三期临床;最近,Magainin制药公司宣布,他们生产的爪蟾皮肤抗菌肽Magainin类似物MSI-78用于治疗926例糖尿病患者因多种细菌感染而引起足部溃疡的III期临床结果表明,MSI-78与ofloxacin有同样的效果,但产生更小的副作用。Intrabiotics公司生产的抗菌肽IB-367已获准用于治疗癌症病人因多种细菌感染而引起的口腔溃疡一期临床试验;AppliedMicrobiology公司与Astra公司合作用抗菌肽nisin治疗胃溃疡的临床试验也取得良好的疗效。国外学者也已报道从东方铃蟾(Bombina orientalis)和花铃蟾(Bombina variegata)中分离出若干具广谱抗微生物活性的多肽类物质,如Bombinin和BLP-like多肽。Many amphibians are widely used in traditional Chinese medicine and ethnic medicine in China, such as Chinese toad (Bufo gargarizans), large webbed bell toad (Bombina maxima), black-spotted frog (pelophylax nigromaculata), marsh frog (Hylarana guentheri) and marsh frog ( Euphlyctis limnocharis) etc. The skin and viscera of these amphibians have a wide range of pharmacological activities and clinical curative effects. It has been reported that the pharmacological activities include broad-spectrum antimicrobial effects, anti-tumor effects, local anesthesia, analgesia, immune regulation, and cardiovascular system effects. In foreign countries, the search for specific pharmacologically active monomeric compounds in amphibian skin has become a hot spot for new drug inventions. According to foreign literature reports, the antibacterial peptide Magainin obtained from the skin secretion of Xenopus laevis has broad-spectrum antimicrobial effects and has Anti-tumor activity, has been approved as a broad-spectrum antibacterial drug in the United States, and its genetic engineering products have entered Phase III clinical trials; recently, Magainin Pharmaceuticals announced that the Xenopus skin antimicrobial peptide Magainin analog MSI-78 they produced was used to treat 926 cases Phase III clinical results of diabetic patients with foot ulcers caused by various bacterial infections showed that MSI-78 had the same effect as ofloxacin, but produced fewer side effects. The antibacterial peptide IB-367 produced by Intrabiotics has been approved for the first phase of clinical trials in the treatment of oral ulcers caused by various bacterial infections in cancer patients; the clinical trial of the antimicrobial peptide nisin in the treatment of gastric ulcers in cooperation between Applied Microbiology and Astra has also achieved good results Efficacy. Foreign scholars have also reported that several polypeptides with broad-spectrum antimicrobial activity have been isolated from Bombina orientalis and Bombina variegata, such as Bombinin and BLP-like polypeptides.
我国对两栖类药物的应用有悠久的历史,但对其活性成分和药理性质的研究主要集中于生物碱等有机小分子,对其皮肤活性肽类物质的研究还较少。对两栖类皮肤抗菌肽的研究还未见报道。大蹼铃蟾(Bombina maxima)主要分布于我国的云南、四川省,是我国的特色资源动物之一,也是特色的民族民间药物。The application of amphibian drugs has a long history in my country, but the research on their active ingredients and pharmacological properties mainly focuses on small organic molecules such as alkaloids, and there are few researches on their skin active peptides. The research on amphibian skin antimicrobial peptides has not been reported yet. Bombina maxima is mainly distributed in Yunnan and Sichuan provinces in my country. It is one of the characteristic resource animals in my country and also a characteristic folk medicine.
发明人将本发明的大蹼铃蟾抗菌肽全序列结构经蛋白质数据库进行搜寻比较,未发现有任何相同多肽。The inventor searched and compared the full sequence structure of the bombesin antimicrobial peptide of the present invention through protein databases, and found no identical polypeptides.
本发明的目的是基于上述现有技术基础,提供一种具有广谱抗微生物(包括革兰氏阳性细菌,革兰氏阴性细菌、真菌)活性的大蹼铃蟾抗菌肽及其制备方法和在制药中的应用。The object of the present invention is based on above-mentioned prior art basis, provides a kind of broad-spectrum antimicrobial (comprising Gram-positive bacteria, Gram-negative bacteria, fungus) active bombesin and preparation method thereof applications in pharmaceuticals.
为了实现本发明的目的,本发明提供了如下技术方案:In order to realize the purpose of the present invention, the present invention provides following technical scheme:
大蹼铃蟾抗菌肽,为我们首次从中国两栖类动物大蹼铃蟾皮肤分泌物中分离得到的一种单链多肽,分子量2697.6,等电点10.2,多肽一级全序列结构为:甘氨酸-异亮氨酸-甘氨酸-甘氨酸-缬氨酸-亮氨酸-亮氨酸-丝氨酸-丙氨酸-甘氨酸-赖氨酸-丙氨酸-丙氨酸-亮氨酸-赖氨酸-甘氨酸-亮氨酸-丙氨酸-赖氨酸-缬氨酸-亮氨酸-丙氨酸-丙氨酸-赖氨酸-酪氨酸-丙氨酸-天冬酰胺-酰胺化天冬酰胺(NH2-GIGGVLLSAGKAALKGLAKVLAAKYANN-NH2)。Bombina grandis antimicrobial peptide is a single-chain polypeptide isolated from the skin secretion of the Chinese amphibian Bombina grandis for the first time, with a molecular weight of 2697.6 and an isoelectric point of 10.2. The primary complete sequence structure of the polypeptide is: glycine- Isoleucine-Glycine-Glycine-Valine-Leucine-Leucine-Serine-Alanine-Glycine-Lysine-Alanine-Alanine-Leucine-Lysine-Glycine -Leucine-Alanine-Lysine-Valine-Leucine-Alanine-Alanine-Lysine-Tyrosine-Alanine-Asparagine-Amidated Asparagine (NH 2 -GIGGVLLSAGKAALKGLAKVLAAKYANN-NH 2 ).
大蹼铃蟾抗菌肽的制备方法,是将活体大蹼铃蟾用水清洗干净,置于带盖的玻璃容器中,滴加无水乙醚(1升体积容积加1毫升无水乙醚),密闭容器3-5分钟,可见大量的泡沫状物质从大蹼铃蟾皮肤分泌出来,收集分泌物,离心(10000rpm,20分钟)、冷冻干燥后,经DEAE-Sephadex A-50离子交换后,收取所得峰I经Sephadex G-50凝胶过滤后取峰IV,峰IV再经CM-Sephadex C-25离子交换,取第三步柱层析分离出的峰II,再经高效液相色谱(HPLC)反相C18柱分离纯化,取第四步HPLC反相C18柱层析分离出的峰II即可(如图4箭头所示)。然后用高效液相色谱HPLC方法鉴定其纯度,分子量测定采用快原子轰击质谱法(Fast atom bombardment mass spectrometry,FAB-MS),等电聚焦电泳测定等电点,用自动氨基酸测序仪测定氨基酸序列结构。The preparation method of Bombina grandis antimicrobial peptide is to clean the living Bombina grandis with water, place it in a glass container with a cover, add anhydrous ether dropwise (1 liter of volume adds 1 milliliter of anhydrous ether), and seal the container 3-5 minutes, it can be seen that a large amount of foamy substance is secreted from the skin of Bombina maxima, collect the secretion, centrifuge (10000rpm, 20 minutes), freeze-dry, and collect the obtained peak after ion exchange with DEAE-Sephadex A-50 I gets peak IV after Sephadex G-50 gel filtration, and peak IV is ion-exchanged with CM-Sephadex C-25 again, gets the peak II that the third step column chromatography separates, and then reacts through high-performance liquid chromatography (HPLC) Phase C18 column separation and purification, take the peak II separated by the fourth step of HPLC reverse phase C18 column chromatography (as shown by the arrow in Figure 4). Then use high-performance liquid chromatography (HPLC) to identify its purity, determine its molecular weight by fast atom bombardment mass spectrometry (Fast atom bombardment mass spectrometry, FAB-MS), determine its isoelectric point by isoelectric focusing electrophoresis, and use an automatic amino acid sequencer to determine its amino acid sequence structure .
大蹼铃蟾抗菌肽作为制备广谱抗微生物药的应用。The use of the bombesin antimicrobial peptide as a broad-spectrum antimicrobial drug.
下面用本发明的大蹼铃蟾抗菌肽的药理实验结果来说明本发明的药效作用和有益效果:Below the pharmacological experiment result of bombesin of the present invention is used to illustrate the drug effect and beneficial effect of the present invention:
1,大蹼铃蟾抗菌肽抑制细菌生长的作用:1. The effect of bombesin on inhibiting bacterial growth:
抗菌活性检测,采用杯碟法,培养基为普通琼脂培养基。分别注入加热融化的培养基20ml于平皿中作为底层,使其在皿底内均匀摊布,凝固后,另取培养基适量加热融化后,分别在每皿中加入5ml菌悬液,摇匀,使其在底层上均匀摊布,作为菌层。冷却后,在平皿中等距离均匀放入已消毒的不锈钢杯6个。第一个钢杯加入0.3mg/ml浓度的待测化合物溶液0.1ml,其余钢杯采用二倍稀释法加入样品液,37℃培养,观察抑菌圈大小。抑菌圈10mm以上的作为最小抑菌浓度(minimal inhibitory concentration,MIC)。细菌菌株来源于昆明医学院第一附属医院,此试验重复四次,取平均值,结果如表1。The antibacterial activity was detected by the cup and saucer method, and the medium was ordinary agar medium. Inject 20ml of heated and melted medium into the plate as the bottom layer, spread it evenly in the bottom of the plate, after solidification, take another appropriate amount of medium and heat and melt, add 5ml of bacterial suspension to each plate, shake well, Spread it evenly on the bottom layer as a bacterial layer. After cooling, put 6 sterilized stainless steel cups evenly in the plate at equal distances. Add 0.1ml of the test compound solution at a concentration of 0.3mg/ml to the first steel cup, add the sample solution to the remaining steel cups by doubling dilution method, incubate at 37°C, and observe the size of the inhibition zone. The bacteriostatic zone above 10mm was regarded as the minimum inhibitory concentration (minimal inhibitory concentration, MIC). The bacterial strains were obtained from the First Affiliated Hospital of Kunming Medical College. The test was repeated four times and the average value was taken. The results are shown in Table 1.
2,大蹼铃蟾抗菌肽抑制真菌生长的作用:2. The effect of bombesin on inhibiting the growth of fungi:
抗真菌活性检测,采用杯碟法。培养基为改良沙保氏(Sabousand)培养基,分别注入加热融化的培养基20ml于平皿中作为底层,使其在皿底内均匀摊布,凝固后,另取培养基适量加热融化后,分别在每皿中加入5ml菌悬液,摇匀,使其在底层上均匀摊布,作为菌层。冷却后,在平皿中等距离均匀放入已消毒的不锈钢杯6个。第一个钢杯加入0.3mg/ml浓度的待测化合物溶液0.1ml,其余钢杯采用二倍稀释法加入样品液,37℃培养,观察抑菌圈大小。抑菌圈10mm以上的作为最小抑菌浓度(minimal inhibitory concentration,MIC)。真菌株来源于云南大学微生物研究所,此试验重复三次,取平均值,结果如表2。Antifungal activity was detected by the cup and saucer method. The culture medium is improved Sabousand culture medium, inject 20ml of heated and melted culture medium into the plate as the bottom layer, spread it evenly in the bottom of the plate, after solidification, take another appropriate amount of culture medium and heat and melt it, respectively Add 5ml of bacterial suspension to each dish, shake well, and spread it evenly on the bottom layer as a bacterial layer. After cooling, put 6 sterilized stainless steel cups evenly in the plate at equal distances. Add 0.1ml of the test compound solution at a concentration of 0.3mg/ml to the first steel cup, add the sample solution to the remaining steel cups by doubling dilution method, incubate at 37°C, and observe the size of the inhibition zone. The bacteriostatic zone above 10mm was regarded as the minimum inhibitory concentration (minimal inhibitory concentration, MIC). The fungal strain comes from the Institute of Microbiology, Yunnan University. This test was repeated three times, and the average value was taken. The results are shown in Table 2.
表1,大蹼铃蟾抗菌肽抑制细菌生长的作用:
由表1可见,大蹼铃蟾抗菌肽第一步DEAE-Sephadex A-50离子交换粗品及纯化大蹼铃蟾抗菌肽均具有显著的抑制细菌(包括革兰氏阳性细菌,革兰氏阴性细菌)生长的作用,而且与文献报道的其他来源抗菌多肽相比,大蹼铃蟾抗菌肽的抗菌活性平均高5-20倍。As can be seen from Table 1, the first step of bombesin antimicrobial peptide DEAE-Sephadex A-50 ion exchange crude product and purified bombesin antimicrobial peptide all have significant inhibition of bacteria (comprising gram-positive bacteria, gram-negative bacteria ) growth, and compared with other sources of antibacterial peptides reported in the literature, the antibacterial activity of bombesin antibacterial peptides is 5-20 times higher on average.
表2,大蹼铃蟾抗菌肽抑制真菌生长的作用:
由表2可见,除抑制细菌生长外,大蹼铃蟾抗菌肽第一步DEAE-SephadexA-50离子交换粗品及纯化大蹼铃蟾抗菌肽均具有显著的抑制真菌生长的作用,而且与其他来源抗菌多肽相比,抗真菌活性平均也高5-20倍。It can be seen from Table 2 that, in addition to inhibiting bacterial growth, the first step of bombesin antimicrobial DEAE-SephadexA-50 ion-exchange crude product and purified bombesin antibacterial peptide all have a significant effect on inhibiting fungal growth, and compared with other sources Compared with antibacterial peptides, the antifungal activity is also 5-20 times higher on average.
从上述实验结果可得出本发明大蹼铃蟾抗菌肽的有益效果在于:Can draw from above-mentioned experimental result that the beneficial effect of bombesin macrobrain antimicrobial peptide of the present invention is:
大蹼铃蟾抗菌肽粗品及纯化大蹼铃蟾抗菌肽均有显著的抑制细菌和真菌生长的作用,所用微生物菌株包括:大肠杆菌、金黄色葡萄球菌、绿脓杆菌、痢疾杆菌、白色念珠菌、青霉、米曲霉等,结果表明大蹼铃蟾抗菌肽具广谱抗微生物活性(包括革兰氏阳性细菌,革兰氏阴性细菌,真菌;MIC在1-15μg/ml范围内),而且与其他来源抗菌多肽相比,抗菌活性平均也高5-20倍。因此,本发明的大蹼铃蟾抗菌肽是一种首次从中国特色药用生物资源中研制的具有广谱抗微生物活性的生物活性多肽。Both the crude product and the purified bombesin antimicrobial peptide have a significant effect on inhibiting the growth of bacteria and fungi. The microbial strains used include: Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Shigella, Candida albicans , Penicillium, Aspergillus oryzae, etc., the results showed that bombesin had broad-spectrum antimicrobial activity (including Gram-positive bacteria, Gram-negative bacteria, fungi; MIC was in the range of 1-15μg/ml), and Compared with other sources of antibacterial peptides, the antibacterial activity is also 5-20 times higher on average. Therefore, the bombesin of the present invention is a biologically active polypeptide with broad-spectrum antimicrobial activity developed from Chinese characteristic medicinal biological resources for the first time.
下面结合附图用实施例来进一步说明本发明的实质性内容,但本发明的内容并不局限于此。The substantive content of the present invention will be further described below with reference to the accompanying drawings, but the content of the present invention is not limited thereto.
图1为本发明大蹼铃蟾抗菌肽的DEAE-Sephadex A-50离子交换层析图。Fig. 1 is the DEAE-Sephadex A-50 ion exchange chromatogram of bombesin of the present invention.
图2为本发明大蹼铃蟾抗菌肽的Sephadex G-50凝胶过滤层析图。Fig. 2 is a Sephadex G-50 gel filtration chromatogram of bombesin of the present invention.
图3为本发明大蹼铃蟾抗菌肽的CM-Sephadex C-25离子交换层析图。Fig. 3 is the CM-Sephadex C-25 ion-exchange chromatogram of bombesin of the present invention.
图4为本发明大蹼铃蟾抗菌肽的HPLC反相C18柱层析图。Fig. 4 is an HPLC reversed-phase C18 column chromatogram of bombembin of the present invention.
实施例:Example:
1,制备大蹼铃蟾抗菌肽:1. Preparation of bombesin antimicrobial peptide:
活体大蹼铃蟾用水清洗干净,将大蹼铃蟾置于带盖的玻璃容器中,滴加无水乙醚(1升体积容积加1毫升无水乙醚),密闭容器3-5分钟,可见大量的泡沫状物质从大蹼铃蟾皮肤分泌出来,收集分泌物,离心(10000rpm,20分钟)、冷冻干燥、低温保存。第一步:DEAE Sephadex A-50离子交换,按上述方法获得原材料大蹼铃蟾分泌物冻干粉,冻干粉溶解于0.05M Tris-HCl,含10mMEDTA,pH7.3的缓冲液,装于3.5KDa透析袋,于同样缓冲液透析12小时;DEAESephadex A-50(Pharmacia产品)阴离子交换柱(500mm长,26mm直径)经0.05MTris-HCl,含10mM EDTA,pH7.3缓冲液平衡,已透析好的样品上柱,经两个柱体积同样缓冲液冲洗至穿透峰被完全洗脱,再用含NaCl的缓冲液进行梯度洗脱,收集穿透峰I。Clean the living Bombina grandis with water, put the Bombina grandis in a glass container with a cover, add anhydrous ether (1 liter of volume plus 1 ml of anhydrous ether), and seal the container for 3-5 minutes. The foamy substance was secreted from the skin of Bombina maxima, and the secretion was collected, centrifuged (10000rpm, 20 minutes), freeze-dried, and stored at low temperature. The first step: DEAE Sephadex A-50 ion exchange, according to the above method to obtain the lyophilized powder of the raw material Bombina grandis secretion, the lyophilized powder was dissolved in 0.05M Tris-HCl, containing 10mM EDTA, pH7.3 buffer, packed in 3.5KDa dialysis bag, dialyzed in the same buffer solution for 12 hours; DEAESephadex A-50 (Pharmacia product) anion exchange column (500mm long, 26mm diameter) equilibrated with 0.05MTris-HCl, containing 10mM EDTA, pH7.3 buffer solution, dialyzed A good sample is put on the column, washed with two column volumes of the same buffer until the breakthrough peak is completely eluted, and then gradient eluted with a buffer containing NaCl to collect the breakthrough peak I.
第二步,Sephadex G-50凝胶过滤:第一步得到的活性成分穿透峰I冻干,溶解于0.1M Na2HPO4-NaH2PO4,pH6.0缓冲液,上样于Sephadex G-50(Pharmacia产品)凝胶过滤柱(1000mm长,26mm直径),用同样缓冲液洗脱,收集峰IV。The second step, Sephadex G-50 gel filtration: the active ingredient breakthrough peak I obtained in the first step was lyophilized, dissolved in 0.1M Na 2 HPO 4 -NaH 2 PO 4 , pH 6.0 buffer, and loaded on Sephadex G-50 (Pharmacia product) gel filtration column (1000 mm long, 26 mm diameter), eluted with the same buffer, and collected peak IV.
第三步,CM Sephadex C-25离子交换:凝胶过滤得到的活性成分峰IV上样品于经0.1M Na2HPO4-NaH2PO4,pH6.0缓冲液平衡的CH Sephadex C-25(Pharmacia产品)阳离子交换柱(300mm长,26mm直径),再用含NaCl的缓冲液进行梯度洗脱,收集峰II。The third step, CM Sephadex C-25 ion exchange : the sample on the active ingredient peak IV obtained by gel filtration was placed in CH Sephadex C-25 ( Pharmacia product) cation exchange column (300mm long, 26mm diameter), carry out gradient elution with the buffer solution containing NaCl again, collect peak II.
第四步,反相高压液相层析(RP-HPLC):CM Sephadex C-25离子交换得到的活性成分峰II以水(含0.1%三氟乙酸):乙晴(含0.1%三氟乙酸)构成的洗脱系统进行梯度洗脱,收集高压液相层析HPLC反相C18柱层析峰(如图4箭头标记)即为大蹼铃蟾抗菌肽。The fourth step, reversed-phase high-pressure liquid chromatography (RP-HPLC): CM Sephadex C-25 ion exchange obtained active ingredient peak II with water (containing 0.1% trifluoroacetic acid): acetonitrile (containing 0.1% trifluoroacetic acid ) constitutes an elution system for gradient elution, and collects high-pressure liquid chromatography HPLC reverse-phase C18 column chromatography peaks (marked by arrows in Figure 4) that are bombesin.
2,分子量测定采用快原子轰击质谱法(Fast atom bombardment massspectrometry,FAB-MS),以甘油:间硝基苄醇:二甲亚砜(1∶1∶1,V∶V∶V,体积比)为底物,Cs+作为轰击粒子,电流为1μA,发射电压为25Kv。2. The molecular weight was determined by Fast atom bombardment mass spectrometry (FAB-MS), using glycerol: m-nitrobenzyl alcohol: dimethyl sulfoxide (1:1:1, V:V:V, volume ratio) As the substrate, Cs + as the bombardment particles, the current is 1μA, and the emission voltage is 25Kv.
3,纯化的大蹼铃蟾抗菌肽用高效液相色谱HPLC方法鉴定其纯度,分子量测定采用快原子轰击质谱法,等电聚焦电泳测定等电点,用自动氨基酸测序仪测定氨基酸序列结构。3. The purity of the purified bombesin was identified by high performance liquid chromatography (HPLC), the molecular weight was determined by fast atom bombardment mass spectrometry, the isoelectric point was determined by isoelectric focusing electrophoresis, and the amino acid sequence structure was determined by an automatic amino acid sequencer.
通过上述方法制备的大蹼铃蟾抗菌肽,是我们首次从中国两栖类动物大蹼铃蟾皮肤分泌物中分离得到的一种单链多肽,分子量2697.6,等电点10.2,多肽全序列一级结构为:甘氨酸-异亮氨酸-甘氨酸-甘氨酸-缬氨酸-亮氨酸-亮氨酸-丝氨酸-丙氨酸-甘氨酸-赖氨酸-丙氨酸-丙氨酸-亮氨酸-赖氨酸-甘氨酸-亮氨酸-丙氨酸-赖氨酸-缬氨酸-亮氨酸-丙氨酸-丙氨酸-赖氨酸-酪氨酸-丙氨酸-天冬酰胺-酰胺化天冬酰胺(NH2-GIGGVLSAGKAALKGLAKVLAAKYANN-NH2)。大蹼铃蟾抗菌肽具有广谱抗微生物活性和显著的抑制细菌和真菌生长作用,作为广谱抗微生物物质在制备治微生物感染疾病药物的应用。The Bombina grandis antimicrobial peptide prepared by the above method is a single-chain polypeptide isolated from the skin secretion of the Chinese amphibian Bombina major for the first time, with a molecular weight of 2697.6, an isoelectric point of 10.2, and a complete sequence of the polypeptide at the first level The structure is: glycine-isoleucine-glycine-glycine-valine-leucine-leucine-serine-alanine-glycine-lysine-alanine-alanine-leucine- Lysine-Glycine-Leucine-Alanine-Lysine-Valine-Leucine-Alanine-Alanine-Lysine-Tyrosine-Alanine-Asparagine- Amidated asparagine (NH 2 -GIGGVLSAGKAALKGLAKVLAAKYANN-NH 2 ). The bombesin antimicrobial peptide has a broad-spectrum antimicrobial activity and a significant effect of inhibiting the growth of bacteria and fungi, and is used as a broad-spectrum antimicrobial substance in the preparation of drugs for treating microbial infection diseases.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 00122414 CN1336383A (en) | 2000-07-29 | 2000-07-29 | Giant web bombinin and its prepn. and pharmaceutical application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 00122414 CN1336383A (en) | 2000-07-29 | 2000-07-29 | Giant web bombinin and its prepn. and pharmaceutical application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1336383A true CN1336383A (en) | 2002-02-20 |
Family
ID=4589253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 00122414 Pending CN1336383A (en) | 2000-07-29 | 2000-07-29 | Giant web bombinin and its prepn. and pharmaceutical application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1336383A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102133235A (en) * | 2011-03-07 | 2011-07-27 | 哈尔滨工业大学 | Toad peptide antibiotics for preparing medicine for treating phthisis |
CN101031583B (en) * | 2004-08-18 | 2013-06-05 | 诺瓦生命科学有限公司 | Antimicrobial peptides containing arginine and/or lysine motif |
CN104223121A (en) * | 2014-09-16 | 2014-12-24 | 重庆馗旭生物科技股份有限公司 | Extracting device for giant salamander skin mucus and extracting method |
CN105837674A (en) * | 2016-03-08 | 2016-08-10 | 无限极(中国)有限公司 | Bombina orientalis polypeptide, and preparation method and application thereof |
CN110684098A (en) * | 2019-10-09 | 2020-01-14 | 江苏医药职业学院 | Method for preparing oriental fire-bellied toad antibacterial peptide bombinin and its application |
-
2000
- 2000-07-29 CN CN 00122414 patent/CN1336383A/en active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101031583B (en) * | 2004-08-18 | 2013-06-05 | 诺瓦生命科学有限公司 | Antimicrobial peptides containing arginine and/or lysine motif |
CN103360486A (en) * | 2004-08-18 | 2013-10-23 | 诺瓦生命科学有限公司 | Antimicrobial peptides comprising arginine-and/or lysine-containing motif |
CN102133235A (en) * | 2011-03-07 | 2011-07-27 | 哈尔滨工业大学 | Toad peptide antibiotics for preparing medicine for treating phthisis |
CN102133235B (en) * | 2011-03-07 | 2013-03-20 | 哈尔滨工业大学 | Toad peptide antibiotic medicine for treating phthisis |
CN104223121A (en) * | 2014-09-16 | 2014-12-24 | 重庆馗旭生物科技股份有限公司 | Extracting device for giant salamander skin mucus and extracting method |
CN105837674A (en) * | 2016-03-08 | 2016-08-10 | 无限极(中国)有限公司 | Bombina orientalis polypeptide, and preparation method and application thereof |
CN110684098A (en) * | 2019-10-09 | 2020-01-14 | 江苏医药职业学院 | Method for preparing oriental fire-bellied toad antibacterial peptide bombinin and its application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0652230B1 (en) | Biologically active bactericidal/permeability-increasing protein fragments | |
US5948408A (en) | DNA encoding bactericidal/permeability-increasing proteins | |
US5294605A (en) | Amphiphilic peptide compositions and analogues thereof | |
CN108892719B (en) | Novel humanized antibacterial peptide LL-37 derivative and application thereof | |
CN114181293B (en) | Humanized antibacterial peptide LL-37 modified body and application thereof | |
CN103435686B (en) | Anti-drug resistance bacteriological infection peptide C bf-14 and uses thereof | |
CN102924574B (en) | Antibacterial peptide LZ1 and application of antibacterial peptide in preparation of antibacterial medicament | |
CN1927880A (en) | Odorranagrahami antimicrobialpeptides and application thereof | |
Wenhua et al. | Induction, purification and characterization of an antibacterial peptide scolopendrin I from the venom of centipede Scolopendra subspinipes mutilans | |
US6316594B1 (en) | Antimicrobial peptide isolated from parasilurus asotus and its uses | |
KR101700603B1 (en) | An anti-microbial peptide, Periplanetasin-1 isolated from Periplaneta americana and its synthetic composition | |
CN101333247B (en) | Antimicrobial peptide separated from skin of Northeast China brown frog and applications in antibacterials | |
CN100475840C (en) | Vespa antibacterial peptide and its preparation method and application | |
CN1336383A (en) | Giant web bombinin and its prepn. and pharmaceutical application | |
JPH03504501A (en) | Amphipathic peptides and their uses | |
CN104478996A (en) | New cationic antimicrobial peptide and application thereof | |
CN115043924B (en) | Modified antibacterial peptide and application thereof | |
CN100372869C (en) | Antimicrobial Polypeptide of Brown-spotted Frog and Its Application in Pharmaceuticals | |
CN1336384A (en) | Giant web bombinator skin peptide and its prepn. and pharmaceutical application | |
JP6820251B2 (en) | Peptide having antibiotic activity against pathogens and antibiotic composition containing the same | |
US10100086B2 (en) | Peptide and uses thereof | |
CN100467481C (en) | Antimicrobial peptides of the brown-spotted frog and its application in pharmacy | |
KR101257222B1 (en) | Antibiotic peptides having an antibiotics and comprising antibiotic composition thereof | |
CN1336386A (en) | Giant web bombinator polypeptide and its prepn. and pharmaceutical application | |
CN119264223A (en) | A polypeptide, a composition and its application in preparing antibacterial products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |